Literature DB >> 15920905

Perioperative antimicrobial prophylaxis in urology: a multi-center prospective study.

S Yamamoto1, S Kanamaru, Y Kunishima, S Ichiyama, O Ogawa.   

Abstract

Since there are few published reports regarding the impact of urologic surgery on perioperative infections, an epidemiologic analysis was performed on data from 1,156 open or laparoscopic operations in urology collected by the 21 hospitals participating in this study between September 2002 and August 2003. Prophylactic antibiotics were administered intravenously according to our protocol designed on the basis of the invasiveness and contamination levels. The surgical site infection (SSI) rates following clean, clean-contaminated and contaminated surgery were 1.2%. 5.8% and 23.4%, respectively, while the remote infection (RI) rates were 3.5%. 7.1% and 35.9%, respectively. Methicillin-resistant Staphylococcus aureus (MRSA) was most frequently isolated from SSIs as well as RIs, whereas Enterococcus faecalis and Pseudomonas aeruginosa were more frequently discovered in RIs than in SSIs. Several risk factors for SSI and/or RI, such as older age, high ASA score, obesity, diabetes, preoperative chemotherapy, long operation time and much blood loss, were identified by univariate analysis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15920905     DOI: 10.1179/joc.2005.17.2.189

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  2 in total

1.  Risk factors of surgical site infection after hepatectomy for liver cancers.

Authors:  Shin Kobayashi; Naoto Gotohda; Toshio Nakagohri; Shinichiro Takahashi; Masaru Konishi; Taira Kinoshita
Journal:  World J Surg       Date:  2009-02       Impact factor: 3.282

2.  Optimizing compliance with surgical antimicrobial prophylaxis guidelines in patients undergoing gastrointestinal surgery at a referral teaching hospital in southern Iran: clinical and economic impact.

Authors:  Laleh Mahmoudi; Mehrdad Ghouchani; Motahareh Mahi-Birjand; Alimohammad Bananzadeh; Ali Akbari
Journal:  Infect Drug Resist       Date:  2019-08-06       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.